1H-indazole derivatives act as selective inhibitors of HCN1/HCN2 isoforms over HCN4, offering potential therapeutic applications for pain, CNS disorders, psychiatric disorders, and tinnitus.
1H-indazole derivatives are identified as selective inhibitors of HCN1/HCN2 channels with potential therapeutic applications for pain, CNS disorders, psychiatric disorders, and tinnitus.
High Resolution Image Download MS PowerPoint Slide The invention in this patent application relates to 1 H -indazole derivatives represented herein by formula 1. These compounds are inhibitors of hyperpolarization activated cyclic-nucleotide (HCN) modulated ion channel activity, with a selectivity for the inhibition of HCN1/HCN2 isoforms over the HCN4 isoform. The compounds may provide methods for treating, inhibiting, or ameliorating inflammatory and/or neuropathic pain, CNS disorders, psychiatric disorders, mood disorders, and tinnitus.
Ahmed F. Abdel‐Magid (Mon,) conducted a other in Inflammatory and/or neuropathic pain, CNS disorders, psychiatric disorders, mood disorders, and tinnitus. 1 H -indazole derivatives (HCN ion channel inhibitors) was evaluated. 1H-indazole derivatives act as selective inhibitors of HCN1/HCN2 isoforms over HCN4, offering potential therapeutic applications for pain, CNS disorders, psychiatric disorders, and tinnitus.